Basic investigation of clinical implications: Hepcidin, a molecular key to explain the physiopathology of anemia;Hepcidina: Una molécula clave para explicar la fisiopatología de la anemia

Gastroenterologia y Hepatologia Continuada

Volumn 7, Issue 3, 2008, Pages 119-

  Erce, José Antonio García ^a   Gómez, Manuel Muñoz ^b  

^a HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

^b UNIVERSITY OF MÁLAGA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ATLIZUMAB; BONE MORPHOGENETIC PROTEIN; FERROPORTIN 1; GAMMA INTERFERON; HEPCIDIN; HFE PROTEIN; INTERLEUKIN 1; IRON; PROTEIN P53; TUMOR NECROSIS FACTOR;

ANEMIA; ARTICLE; BLOOD SAMPLING; CANCER PREVENTION; CELL PROLIFERATION; DISEASE ASSOCIATION; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE IDENTIFICATION; GENE MUTATION; HORMONE BLOOD LEVEL; HORMONE DETERMINATION; HORMONE SYNTHESIS; HUMAN; INFLAMMATION; IRON ABSORPTION; IRON METABOLISM; IRON OVERLOAD; IRON TRANSPORT; NEOPLASM; NONHUMAN; PATHOPHYSIOLOGY; PROMOTER REGION; PROTEIN FUNCTION; URINALYSIS;

EID: 65249117440     PISSN: 15781550     EISSN: 15787575     Source Type: Journal    
DOI: 10.1016/S1578-1550(08)73001-8     Document Type: Article

References (21)

1. Krause A, Neitz S, Mägert HJ, Schultz A, Forssmann WG, Schulz-Knappe P, et al. LEAP-1, a novel highly disulfide-bonded human peptide, exhibits antimicrobial activity. FEBS Letters. 2000;480:147-50.
2. Park CH, Valore EV, Waring AJ, Ganz T. Hepcidin, a urinary antimicrobial peptide synthesized in the liver. J Biol Chem. 2001;276:7806-10.
3. Del Castillo Rueda A, De Portugal Alvarez J. Hepcidina, una nueva proteína en la homeostasis del hierro. An Med Interna. 2003;20:605-6.
4. Hugman A. Hepcidin: an important new regulator of iron homeostasis. Clin Lab Haem. 2006;28:75-83.
5. Sow FB, Florence WC, Satoskar AR, Schlesinger LS, Zwilling BS, Lafuse W. P. Expression and localization of hepcidin in macrophages: a role in host defense against tuberculosis. Leukoc Biol. 2007. [En prensa].
6. Atanasiu V, Manolescu B, Stoian I. Hepcidin - central regulador of iron metabolism. Eur J Haematol. 2007;44:25-33.
7. Muñoz M, Campos A, García-Erce JA, Ramírez G. Fisiopatología del metabolismo del hierro: implicaciones diagnósticas y terapéuticas. Nefrología. 2005;25:9-19.
8. Pietrangelo A. Molecular insights into the pathogenesis of hereditary haemochromatosis. Gut. 2006;55:564-8.
9. Weiss G, Goodnough LT. Anemia of Chronic Disease. N Engl J Med. 2005;352:1011-23.
10. Muñoz M, Leal-Noval R, García-Erce JA, Naviera E. Prevalencia y tratamiento de la anemia en el paciente crítico. Med Intensiva. 2007;31:388-98.
11. Nemeth E, Valore EV, Territo M, Schiller G, Lischenstein, Ganz T. Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein. Blood. 2003;101:2461-3.
12. Openheimer JS. Iron and its relation to immunity and infectious diseases. J Nutr. 2001;131:616S-631S.
13. Weizer-Stern O, Adamsky K, Margalit O, Ashur-Fabian O, Givol D, Amariglio N, et al. Hepcidin, a key regulator of iron metabolism, is transcriptionally activated by p53. Br J Haematol. 2007;138:253-62.
14. De Domenico I, Ward DM, Kaplan J. Hepcidin regulation: ironing out the details. J Clin Invest. 2007;117:1755-8.
15. Gardenghi S, Marongui MF, Ramos P, Guy E, Breda L, Chadburn A, et al. Inneffective erythropoiesis in betha-thalassemia is characterized by increased iron absorption mediated by down-regulation of hepcidin and up-regulation of ferroportin. Blood. 2007;109:5027-35.
16. Kemna EHJM, Tjalsma H, Podust VN, Swinkels DW. Mass spectrometry-based hepcidin measurements in serum and urine: analytical aspects and clinical implications. Clim Chem. 2007:53:620-8.
17. Murphy AT, Witcher DR, Luan P. Quantitation of hepcidin from human and mouse serum using liquid chromatography tandem mass spectrometry. Blood. 2007;110:1048-54.
18. Roe MA. Serum prohepcidin concentration: no association with iron absorption in healthy men; and no relationship with iron status in men carrying HFE mutations, hereditary haemochromatosis patients undergoing phlebotomy treatment, o pregnant women. Br J Nutr. 2007;91:544-9.
19. Kawabata H, Tomosugi N, Kanda J, Tanaka Y, Yoshizaki K, Uchiyama T. Antiinterleukin 6 receptor antibody tocilizumab reduces the level of serum hepcidin in patients with multicentric Castleman's disease. Haematologica. 2007;92:857-8.
20. Wagner PW. La hepcidina, la grande dama del hierro. 2006. Disponible en: http://www.lms-group.com/ITO/Articles/pwagnergrauesp.pdf
21. Camaschella C, Pagani A, Poggiali E, Silvestre L. Screening hemochromatosis and iron overload. Hematology Education. 2007;1:18-23.